MX2023006768A - Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. - Google Patents
Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo.Info
- Publication number
- MX2023006768A MX2023006768A MX2023006768A MX2023006768A MX2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A MX 2023006768 A MX2023006768 A MX 2023006768A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- talazoparib
- homologous recombination
- identifying
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 title abstract 4
- 229950004550 talazoparib Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006801 homologous recombination Effects 0.000 abstract 4
- 238000002744 homologous recombination Methods 0.000 abstract 4
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 2
- 210000004602 germ cell Anatomy 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a un método de identificación de un tumor metastásico que se ha determinado que presenta una mutación en los genes de la vía de recombinación homóloga, que es sensible al tratamiento con talazoparib, o una sal farmacéuticamente aceptable del mismo, y a métodos de tratamiento del mismo, que comprenden a) la determinación de una puntuación de deficiencia de recombinación homóloga a partir de una biopsia del tumor metastásico; y b) administrar talazoparib, o una sal farmacéuticamente aceptable del mismo, si la puntuación de deficiencia de recombinación homóloga es de al menos el 33%, en donde la mutación no es BRCA1 de línea germinal o BRCA2 de línea germinal. La presente invención también se refiere a un método de selección de un sujeto que se ha determinado que tiene un tumor metastásico con una mutación en los genes de la vía de recombinación homóloga, para su tratamiento con talazoparib, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122453P | 2020-12-07 | 2020-12-07 | |
| PCT/IB2021/061372 WO2022123427A1 (en) | 2020-12-07 | 2021-12-06 | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006768A true MX2023006768A (es) | 2023-06-19 |
Family
ID=79025076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006768A MX2023006768A (es) | 2020-12-07 | 2021-12-06 | Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240052423A1 (es) |
| EP (1) | EP4256088A1 (es) |
| JP (1) | JP2023551968A (es) |
| KR (1) | KR20230118597A (es) |
| CN (1) | CN116802321A (es) |
| CA (1) | CA3203814A1 (es) |
| MX (1) | MX2023006768A (es) |
| WO (1) | WO2022123427A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| EP2531033A4 (en) | 2010-02-03 | 2013-07-31 | Biomarin Pharm Inc | POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES |
| KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| BR112013009117A2 (pt) | 2010-10-21 | 2016-07-19 | Biomarin Pharm Inc | sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo. |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| SG11201700734RA (en) | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| JP2018536700A (ja) | 2015-10-26 | 2018-12-13 | メディヴェイション テクノロジーズ， エルエルシー | Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療 |
| CA3087060A1 (en) * | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
-
2021
- 2021-12-06 US US18/265,656 patent/US20240052423A1/en active Pending
- 2021-12-06 CN CN202180093132.1A patent/CN116802321A/zh active Pending
- 2021-12-06 CA CA3203814A patent/CA3203814A1/en active Pending
- 2021-12-06 KR KR1020237022426A patent/KR20230118597A/ko active Search and Examination
- 2021-12-06 EP EP21831108.2A patent/EP4256088A1/en active Pending
- 2021-12-06 WO PCT/IB2021/061372 patent/WO2022123427A1/en active Application Filing
- 2021-12-06 MX MX2023006768A patent/MX2023006768A/es unknown
- 2021-12-06 JP JP2023534087A patent/JP2023551968A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023551968A (ja) | 2023-12-13 |
| CN116802321A (zh) | 2023-09-22 |
| WO2022123427A1 (en) | 2022-06-16 |
| KR20230118597A (ko) | 2023-08-11 |
| US20240052423A1 (en) | 2024-02-15 |
| CA3203814A1 (en) | 2022-06-16 |
| EP4256088A1 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mendoza et al. | The biology of retinoblastoma | |
| Thacker | The RAD51 gene family, genetic instability and cancer | |
| Campeau et al. | Hereditary breast cancer: new genetic developments, new therapeutic avenues | |
| Curia et al. | MUTYH: Not just polyposis | |
| JP2018525437A5 (es) | ||
| Manenti et al. | Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression | |
| WO2018204777A3 (en) | Methods for identification and modification of lncrna associated with target genotypes and phenotypes | |
| Dunwell et al. | Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia | |
| Qureshi et al. | Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan | |
| Tokarz et al. | Role of mitochondria in carcinogenesis | |
| JP2018510884A5 (es) | ||
| Gutiérrez‐Enríquez et al. | About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants | |
| ATE488529T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren | |
| WO2003032813A3 (en) | Methods for the treatment of carcinoma | |
| Lee et al. | The similarities and differences between intracranial and spinal ependymomas: A review from a genetic research perspective | |
| MX2023006768A (es) | Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo. | |
| TW200512198A (en) | 5-arylpyrimidines as anticancer agents | |
| Mendiola et al. | Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32 | |
| Noë et al. | Pancreatic cancer pathology viewed in the light of evolution | |
| DE50211672D1 (de) | Urokinase-inhibitoren | |
| Fontebasso et al. | Pediatric brain tumors: genomics and epigenomics pave the way | |
| WO2006017317A3 (en) | Method for the treatment of disease | |
| Namgung | Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1 | |
| Kravets et al. | Clinical and pathological prognostic factors in patients with stage III–IVA-B oral squamous cell carcinoma | |
| Jamil et al. | Association of EGFR gene polymorphism in head and neck cancer patients with tobacco and alcohol consuming habits |